Recombinant Anti-DLL4 x Anti-VEGF Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-DLL4 antibody variable domain is fused to CH1 and the other scFv from an anti-VEGF antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Solid tumors therapy.